Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) is a whole-joint disorder involving cartilage degeneration, synovial inflammation, subchondral bone remodeling, immune dysregulation, and pain sensitization.Mesenchymal stem/stromal cells (MSCs) and MSC-derived extracellular vesicles (EVs) have shown anti-inflammatory, immunomodulatory, pro-chondrogenic, and analgesic activities in preclinical studies.Human OA studies of MSCbased interventions report variable symptomatic outcomes, including controlled trials without superiority over their comparators, while clinical evaluation of MSC-EVs remains at an early stage.This narrative review synthesized mechanistic, preclinical, clinical, and translational evidence identified through structured searches of PubMed/MEDLINE, Web of Science Core Collection, and Scopus.Current translation is limited by MSC and EV product heterogeneity, inconsistent characterization and potency assessment, variation in delivery and dosing, heterogeneous OA phenotypes, and limited evidence of reproducible structural regeneration.We propose a four-module precision framework integrating product characterization and functional potency, research-oriented patient stratification, multidimensional outcome assessment, and translational validation using microphysiological systems, machine learning, and stratified randomized trials.Existing evidence supports continued investigation of MSC/EV therapies but does not yet establish an optimal 4 / 76 product, dose, or validated product-patient matching strategy.Prospective standardized studies are required before this framework can guide routine clinical treatment selection.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: